Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel and aspirin in patients with mechanical aortic prostheses

Journal of Heart Valve Disease

Volumn 18, Issue 6, 2009, Pages 617-626

  García Rinaldi, Raúl ^a   Carro Pagán, Carlos ^a   Schaff, Hartzell V ^b   McKellar, Stephen H ^b   Thompson III, Jess L ^b   Quiñones, Jeannette ^a   Rodriguez Acosta, Juan F ^a  

^a PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; TICLOPIDINE;

AGED; AORTA VALVE; ARTICLE; DRUG COMBINATION; DRUG EFFECT; FEMALE; FOLLOW UP; HEART DISEASE; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; MALE; MIDDLE AGED; MORTALITY; PUERTO RICO; THROMBOCYTE; THROMBOEMBOLISM; UNITED STATES;

AGED; AORTIC VALVE; ASPIRIN; BLOOD PLATELETS; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PUERTO RICO; THROMBOEMBOLISM; TICLOPIDINE; UNITED STATES;

EID: 77449110963     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Emery RW, Krogh CC, Arom KV, et al. The St. Jude Medical cardiac valve prosthesis. 25 years' experience with single valve replacement. Ann Thorac Surg 2005;79:776-783
2. Butchart EG. Li HH, Payne N, Buchan K, Grunkemeier GL. Twenty years' experience with the Medtronic Hall valve. J Thorac Cardiovasc Surg 2001;121:1090-1100
3. Bach DS, Goldbach M, Sakwa MP, et al. Hemodynamics and early performance of the St. Jude Medical Regent aortic valve prosthesis. J Heart Valve Dis 2001;10:436-442 (Pubitemid 32685058)
4. Koertke H, Zittermann A, Minami K, et al. Lowdose International Normalized Ratio self-management: A promising tool to achieve low complication rates after mechanical heart valve replacement. Ann Thorac Surg 2005;79:1909-1914 (Pubitemid 40804162)
5. Koertke H, Minami K, Boethig D, et al. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation 2003;108(Suppl. II):75-78
6. Ruel M, Chan V, Dedard P, et al. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults <60 years of age. Circulation 2007;116:294-300
7. Khan S, Trento A, DeRobertu M, et al. Twenty year comparison of tissue and mechanical valve replacement. J Thorac Cardiovasc Surg 2001;122:257-269
8. Brown ML, Schaff HV, Lahr BD, et al. Aortic valve replacement in patients aged 50-70 years: Improved outcome with mechanical versus biologic prostheses. J Thorac Cardiovasc Surg 2008;135:878-884
9. Mistiaen W, Van Cauwelaert P, Muylaert P, Sys SU, Harrisson F, Bortier H. Thromboembolic events after aortic valve replacement in elderly patients with a Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg 2004;127:1166-1170 (Pubitemid 38451953)
10. Hartz RS, LoCicero J, III, Kucich V, et al. Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve in the aortic position. J Thorac Cardiovasc Surg 1986;92:684-690 (Pubitemid 17168264)
11. Ribeiro PA, Al Zaibag M, Idris M, et al. Antiplatelet drugs and the incidence of thromboembolic complications of the St. Jude Medical aortic prosthesis in patients with rheumatic heart disease. J Thorac Surg 1986;91:92-98 (Pubitemid 16126373)
12. Rao PS, Solymar L, Mardini MK, Fawzy ME. Anticoagulant therapy in children with prosthetic valves. Ann Thorac Surg 1989;47:589-592 (Pubitemid 19118811)
13. Height SE, Smith MP. Stratagems for anticoagulant therapy following mechanical heart valve replacement. J Heart Valve Dis 1999;8:662-664
14. Becker RC, Eisenberg P, Turpie AG. Pathobiologic features and prevention of thrombotic complications associated with prosthetic valves: Fundamental principles and the contribution of platelets and thrombin. Am Heart J 2001;141:1025-1037 (Pubitemid 32477017)
15. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993;329:524-529 (Pubitemid 23232620)
16. Peters RJG, Mehta SR, Fox AA, et al. Effect of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events. The CURE Study. Circulation 2003;108:1682-1687 (Pubitemid 37243654)
17. McKellar SH, Thompson JL, III, Garcia-Rinaldi R, MacDonald RJ, Sundt TM, III, Schaff HV. Short and long-term efficacy of aspirin and clopidogrel from thromboprophylaxis for mechanical heart valves: An in-vivo study in swine. J Thorac Cardiovasc Surg 2008;136:908-914
18. Schlitt A, Von Bardeleber RS, Ehrlich A, et al. Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thromb Res 2003;109:131-135 (Pubitemid 36428764)
19. CAPRIE Steering Committee. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation. N Engl J Med 2001;345:494-502
20. Bonow RO, Carabello BA, de Leon AC, Jr., et al. ACC/AHA guidelines for the management of patients with valvular Heart disease: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 1998;32:1486-1582
21. Angiolillo DJ, Fernandez Ortiz A, et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management and future perspectives. J Am Coll Cardiol 2007;49:1505-1516 (Pubitemid 46517957)
22. Bonello L, Camoen-Jan L, Argues S, et al. Adjusted clopidogrel loading doses according to vasodilatorstimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-1411 (Pubitemid 351447314)
23. Gurbel, PA, Becker, RC, Mann, KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-1834 (Pubitemid 350007957)
24. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point of care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-856
25. Mahla E, Antonino MJ, Tantry US, Gurbel PA. Point of care platelet function analysis - Ready for Prime Time? J Am Coll Cardiol 2009;53:857-859
26. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting. J Am Coll Cardiol 2005;46:1833-1837
27. Akins CW, Craig Miller D, Turina MI, et al. Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg 2008;85:1490-1495 (Pubitemid 351381711)
28. Heras M, Chesebro F, Fuster V, et al. High risk of thromboembolism early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995;25:1111-1119
29. Gherli T, Colli A, Fragnito C, et al. Comparing warfarin with aspirin after biological aortic valve replacement. Circulation 2004;110:496-500 (Pubitemid 39036177)
30. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 2006;48:1-148
31. Ferguson AD, Dokainish H, Lakkis N. Aspirin and clopidogrel response variability: Review of the published literature. Texas Heart Inst J 2008;35:313-320
32. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251 (Pubitemid 40094733)
33. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: Anew drug-drug interaction. Circulation 2003;107:32-37 (Pubitemid 36070929)
34. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein la gene. Am J Cardiol 2005;96:1095-1099 (Pubitemid 41416601)
35. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300 mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101-108 (Pubitemid 39572762)
36. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thromboelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705-1709 (Pubitemid 41531626)
37. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175
38. Gurbel PA, Bliden, KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting. J Am Coll Cardiol 2005;46:1800-1806